Psychopharmacology

Psychopharmacology英文简介

Official Journal of the European Behavioural Pharmacology Society (EBPS)

Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields:

Human Psychopharmacology: Experimental

This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered.

Human Psychopharmacology: Clinical and Translational

This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects.

Preclinical psychopharmacology: Behavioral and Neural

This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels.

Preclinical Psychopharmacology: Translational

This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways.

Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic

This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.

Psychopharmacology中文简介

《Psychopharmacology》是一本由SPRINGER出版商出版的专业医学期刊，该刊创刊于1959年，刊期Semimonthly，该刊已被国际权威数据库SCI、SCIE收录。在中科院最新升级版分区表中，该刊分区信息为大类学科：医学 3区，小类学科：神经科学 3区；药学 3区；精神病学 3区；在JCR（Journal Citation Reports）分区等级为Q2。该刊发文范围涵盖神经科学等领域，旨在及时、准确、全面地报道国内外神经科学工作者在该领域取得的最新研究成果、工作进展及学术动态、技术革新等，促进学术交流，鼓励学术创新。2021年影响因子为4.415，平均审稿速度较快,2-4周。

中科院分区最新升级版（当前数据版本：2021年12月最新升级版）

大类学科	分区	小类学科	分区	Top期刊	综述期刊
医学	3区	PHARMACOLOGY & PHARMACY 药学 NEUROSCIENCES 神经科学 PSYCHIATRY 精神病学	2区 3区 3区	否	否

JCR分区（当前数据版本：2021-2022年最新版）

JCR分区等级	JCR所属学科	分区	影响因子
Q2	PHARMACOLOGY & PHARMACY	Q2	4.415
	PSYCHIATRY	Q2
	NEUROSCIENCES	Q2

期刊指数

影响因子	h-index	Gold OA文章占比	研究类文章占比	OA开放访问	平均审稿速度
4.415	181	20.13%	88.58%	未开放	较快,2-4周

IF值(影响因子)趋势图